Gefitinib + chemotherapy significantly improved intracranial PFS, PFS, and OS compared with gefitinib alone in patients with untreated EGFR‐mutant NSCLC BM and could be an optional first‐line treatment for these patients. Here, EGFR is linked to non-small cell lung carcinoma.